The AD-like effect of E2 (i.e., blockade of 5-HT clearance) is due to ERβ activation whereas E2’s inhibition of fluvoxamine’s ability to slow serotonin clearance is mediated through the ERα receptor subtype (Benmansour et al., 2012). This evidence concerns the gene ESR2 and Alzheimer disease.